← Eichor
Study identifier: NCT05874674 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

Condition: Dialysis; Complications · Bleeding  ·  Sponsor: Wonju Severance Christian Hospital

PhaseNA
Planned participants100
Who can joinAll sexes, 18 Years to 99 Years
Healthy volunteersYes

About this study

Comparison nafamostat and low molecular weight heparin among dialysis patients

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (1)

Yonsei Unviersity Wonju College of MedicinWŏnju, Kangwondo, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05874674